Brief: Drugs Made In America Acquisition Merger Agreement Provides For Closing Valuation Of $2.85 Billion Including Apqc Acquisition - SEC Filing
Wed 23:05
BRIEF-Drugs Made In America Acquisition Merger Agreement Provides For Closing Valuation Of $2.85 Billion Including Apqc Acquisition - SEC Filing Oct 21 (Reuters) - Drugs Made In America Acquisition Corp. DMAA.O:
DRUGS MADE IN AMERICA ACQUISITION CORP - CO AND PAGC ENTER AMENDMENT TO MERGER AGREEMENT ON OCT 13, 2026 - SEC FILING
DRUGS MADE IN AMERICA ACQUISITION CORP - MERGER AGREEMENT PROVIDES FOR CLOSING VALUATION OF $2.85 BILLION INCLUDING APQC ACQUISITION - SEC FILING
DRUGS MADE IN AMERICA ACQUISITION CORP - AMENDMENT SETS STANDALONE CLOSING VALUATION AT $1.71 BILLION FOR PAGC IF APQC ACQUISITION NOT COMPLETED BY NOV 1
Source text: [ID:n0001213900-26-111421]
Further company coverage: DMAA.O
((Reuters.Briefs@thomsonreuters.com;))